<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484833</url>
  </required_header>
  <id_info>
    <org_study_id>2014-004299-41</org_study_id>
    <nct_id>NCT02484833</nct_id>
  </id_info>
  <brief_title>Erbitux MEtastatic Colorectal Cancer Strategy Study</brief_title>
  <acronym>ERMES</acronym>
  <official_title>Erbitux MEtastatic Colorectal Cancer Strategy Study: A Phase III Randomized Two Arm Study With FOLFIRI + Cetuximab Until Disease Progression Compared to FOLFIRI + Cetuximab for 8 Cycles Followed by Cetuximab Alone Until Disease Progression in First Line Treatment of Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carlo Barone</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To investigate whether cetuximab alone (given until progression or cumulative toxicity)
           after 8 cycles of FOLFIRI + cetuximab results in a non inferior Progression Free
           Survival when compared with continuous FOLFIRI + cetuximab (given until progression or
           cumulative toxicity).

        -  To assess whether an improvement in the incidence of grade 3-4 hematological and
           non-hematological adverse events (AEs) can be achieved in the experimental arm
           (cetuximab alone after 8 cycles FOLFIRI + cetuximab) as compared to the continuous
           chemotherapy arm (FOLFIRI plus cetuximab)

        -  To explore the possibility of using liquid biopsies for molecular profiling as well as
           monitoring treatment activity in mCRC pts receiving cetuximab based therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Survival of patients undergoing therapy with FOLFIRI + cetuximab seems to be related to the
      ability of this treatment to induce a rapid reduction in tumor mass. In the retrospective
      analyses of the FIRE-3 trial ETS was significantly associated with PFS and OS, suggesting
      that ETS reflects the existence of a selected population of patients highly sensitive to
      cetuximab. This permits the assumption that, once this goal has been achieved, further
      exposure to combined antineoplastic treatment (cytotoxic drugs and targeted therapy) may not
      result in improvement or preservation of the result, but only in an increase of side effects
      that will be additional to unavoidable disease progression. In addition, the heavy exposure
      to cytotoxic antineoplastic treatments may lead to bone marrow toxicity, hepatic and renal
      function decreases that could compromise the sequential treatment plan, negatively affecting
      OS. With the availability of an effective treatment such as cetuximab in monotherapy4 without
      major side effects on blood counts and liver and kidney function, the use of this treatment
      alone after achievement of the deepest clinical response could be a viable strategy to
      achieve a good control of the disease, limiting side effects. As shown in several studies
      designed to understand the most effective treatment sequence in colorectal carcinoma, the
      most important factor that influences the overall survival is the possibility to administer
      more lines of effective therapy. As a consequence, a de-intensifying strategy in a subgroup
      of highly selected RAS and BRAF WT population might segregate a group of patients with the
      largest potential for fast-primary treatment. Joining the best induction treatment with the
      expression of patients capability to undergo additional lines of antineoplastic therapy may
      be the way to optimize the continuum of care.

      Recently, several mechanisms of resistance to anti-EGFR therapy have been described, but
      until now none may used early in order to support the treatment choice.Moreover, assessment
      of secondary resistance requires further tissue samples and often it is not really feasible.
      Therefore, a prospective multiple gene mutation analysis could meet the need of
      characterizing primary resistance, whereas liquid biopsy might help to recognize resistance
      occurring early during treatment by means of a simple and repeatable assay. Based on all
      these considerations, the investigators designed a strategy study: a phase III randomized two
      arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab
      for 8 cycles followed by cetuximab alone until disease progression in the first line
      treatment of patients with RAS and BRAF WT metastatic colorectal cancer combined with a
      prospective multiple gene mutation analysis of both tumor tissue and blood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3-4 AEs</measure>
    <time_frame>weekly from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>RR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early tumor shrinkage assessed by Response rate at week 8</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>ETS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cetuximab-related skin toxicity by CTCAE</measure>
    <time_frame>weekly from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>Cetuximab-related skin toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile assessed by CTCAE</measure>
    <time_frame>weekly until from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>Safety profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires</measure>
    <time_frame>every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 weeks</time_frame>
    <description>QoL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>FOLFIRI + Cetuximab until disease progression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI + Cetuximab until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI + Cetuximab followed by Cetuximab alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>FOLFIRI + Cetuximab until disease progression</arm_group_label>
    <arm_group_label>FOLFIRI + Cetuximab followed by Cetuximab alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <arm_group_label>FOLFIRI + Cetuximab until disease progression</arm_group_label>
    <arm_group_label>FOLFIRI + Cetuximab followed by Cetuximab alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of colorectal adenocarcinoma

          -  Diagnosis of metastatic disease

          -  RAS and BRAF wildtype

          -  Measurable disease according to RECIST criteria v1.1

          -  Male or female over 18 years of age

          -  ECOG Performance Status 2

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver and renal function assessed within 14 days before starting
             study treatment

          -  If female and of childbearing potential, have a negative result on a pregnancy test
             performed a maximum of 7 days before initiation of study treatment

          -  If female and of childbearing potential, or if male, agreement to use adequate
             contraception

          -  Signed informed consent obtained at screening

        Exclusion Criteria:

          -  Any contraindication to use cetuximab, irinotecan, 5 FU or folinic acid

          -  Active uncontrolled infections or active disseminated intravascular coagulation

          -  Past or current history of malignancies other than colorectal carcinoma, except for
             curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma
             of the cervix

          -  Pregnancy.

          -  Breastfeeding.

          -  Grade III or IV heart failure (NYHA classification)

          -  Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or
             without stenting within the past 12 months before inclusion in the study

          -  Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta
             blockers or digoxin

          -  Medical or psychological impairments associated with restricted ability to give
             consent or not allowing conduct of the study

          -  Previous chemotherapy for colorectal cancer with the exception of adjuvant treatment,
             completed at least 6 months before entering the study

          -  Participation in a clinical study or experimental drug treatment within 30 days prior
             to study inclusion or during participation in the study

          -  Known or clinically suspected brain metastases

          -  History of acute or subacute intestinal occlusion or chronic inflammatory bowel
             disease or chronic diarrhoea

          -  Severe, non-healing wounds, ulcers or bone fractures

          -  Uncontrolled hypertension

          -  Marked proteinuria (nephrotic syndrome)

          -  Known DPD deficiency (specific screening not required)

          -  Known history of alcohol or drug abuse

          -  A significant concomitant disease which, in the investigating physician's opinion,
             rules out the patient's participation in the study

          -  Absent or restricted legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlo Barone, Prof</last_name>
    <phone>+39 0630154838</phone>
    <email>carlobarone@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universit√† Cattolica del Sacro Cuore - UOC Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00160</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Orlandi, M.D, Ph.D.</last_name>
      <phone>+39 0630156318</phone>
      <email>armando.orlandi@edu.rm.unicatt.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Carlo Barone</investigator_full_name>
    <investigator_title>Clinical Professor and Head of Medical Oncology Department</investigator_title>
  </responsible_party>
  <keyword>First line</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>strategy study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

